Jude cohort, 10 or more years out from cancer therapy and without history of cardiomyopathy, NT-ProBNP levels above the age- and sex-specific 97.5th percentile identified patients with a twofold increased risk for subsequent cardiomyopathy [11]. This evidence concerns the gene NPPB and cancer.